2022
Prefrontal Glutamate Neurotransmission in PTSD: A Novel Approach to Estimate Synaptic Strength in Vivo in Humans
Averill LA, Jiang L, Purohit P, Coppoli A, Averill CL, Roscoe J, Kelmendi B, De Feyter HM, de Graaf RA, Gueorguieva R, Sanacora G, Krystal JH, Rothman DL, Mason GF, Abdallah CG. Prefrontal Glutamate Neurotransmission in PTSD: A Novel Approach to Estimate Synaptic Strength in Vivo in Humans. Chronic Stress 2022, 6: 24705470221092734. PMID: 35434443, PMCID: PMC9008809, DOI: 10.1177/24705470221092734.Peer-Reviewed Original ResearchGlutamatergic synaptic strengthSynaptic strengthPathophysiology of PTSDNovel putative biomarkersTrauma-related psychopathologyMagnetic resonance spectroscopyGlutamate neurotransmissionHealthy controlsNew treatmentsChronic stressPatientsPutative biomarkersEffects of sexPTSDNeurotransmissionPosttraumatic stressAgePsychopathologyEPCPathophysiologyStudy resultsTraumaBiomarkers
2020
Imaging the glutamate synapse
Krystal JH. Imaging the glutamate synapse. Nature Medicine 2020, 26: 165-167. PMID: 32015559, DOI: 10.1038/s41591-020-0760-4.Peer-Reviewed Original Research
2018
The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects
Abdallah CG, De Feyter HM, Averill LA, Jiang L, Averill CL, Chowdhury GMI, Purohit P, de Graaf RA, Esterlis I, Juchem C, Pittman BP, Krystal JH, Rothman DL, Sanacora G, Mason GF. The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects. Neuropsychopharmacology 2018, 43: 2154-2160. PMID: 29977074, PMCID: PMC6098048, DOI: 10.1038/s41386-018-0136-3.Peer-Reviewed Original ResearchConceptsGlutamate-glutamine cyclingGlutamate neurotransmissionAntidepressant effectsKetamine effectsRodent studiesN-methyl-D-aspartate receptor antagonistRapid antidepressant effectsClinician-Administered Dissociative States ScaleEffects of ketamineGlutamine enrichmentKetamine infusionGlutamate releaseKetamine administrationSubanesthetic dosesPsychotomimetic effectsReceptor antagonistNormal salineSchizophrenia pathophysiologyFrontal cortexMRS scansDepressed subjectsKetamineNeurotransmissionPrefrontal cortexPilot study
2016
Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies
Averill LA, Purohit P, Averill CL, Boesl MA, Krystal JH, Abdallah CG. Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies. Neuroscience Letters 2016, 649: 147-155. PMID: 27916636, PMCID: PMC5482215, DOI: 10.1016/j.neulet.2016.11.064.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderPsychiatric disordersStress-related psychiatric disordersAlternative pharmacologic treatmentsPutative neurobiological underpinningsGlutamate-modulating agentsTrauma-related disordersGlutamatergic abnormalitiesGlutamate dysregulationPharmacologic treatmentPharmacologic interventionsGlutamatergic functionGlutamate neurotransmissionMillions of individualsHuman studiesCardinal featuresStress disorderDisordersNeurobiological underpinningsRelated future directionsEvidenceChronicDysfunctionNeurotransmissionSubject data
2008
Capitalizing on Extrasynaptic Glutamate Neurotransmission to Treat Antipsychotic-Resistant Symptoms in Schizophrenia
Krystal JH. Capitalizing on Extrasynaptic Glutamate Neurotransmission to Treat Antipsychotic-Resistant Symptoms in Schizophrenia. Biological Psychiatry 2008, 64: 358-360. PMID: 18694665, DOI: 10.1016/j.biopsych.2008.06.011.Peer-Reviewed Original Research
2007
The NMDA receptor as a therapeutic target in major depressive disorder.
Pittenger C, Sanacora G, Krystal JH. The NMDA receptor as a therapeutic target in major depressive disorder. CNS & Neurological Disorders - Drug Targets 2007, 6: 101-15. PMID: 17430148, DOI: 10.2174/187152707780363267.Peer-Reviewed Original ResearchConceptsMajor depressive disorderNMDA receptorsDepressive disorderNovel antidepressant medicationsCognitive side effectsPotential of drugsAntidepressant medicationAntidepressant propertiesSuch medicationsGlutamatergic neurotransmissionGlutamate receptorsPreclinical studiesPsychotomimetic propertiesSide effectsTherapeutic targetAnimal modelsUseful agentNeurotransmissionReceptorsLines of evidenceMedicationsDisordersDrugsCurrent knowledgeDepression
2006
Decreased Cerebrospinal Fluid Allopregnanolone Levels in Women with Posttraumatic Stress Disorder
Rasmusson AM, Pinna G, Paliwal P, Weisman D, Gottschalk C, Charney D, Krystal J, Guidotti A. Decreased Cerebrospinal Fluid Allopregnanolone Levels in Women with Posttraumatic Stress Disorder. Biological Psychiatry 2006, 60: 704-713. PMID: 16934764, DOI: 10.1016/j.biopsych.2006.03.026.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderPremenopausal womenALLO levelsStress disorderCerebrospinal fluid levelsPTSD re-experiencing symptomsAllopregnanolone levelsOral contraceptivesGABAergic neurotransmissionDHEAS levelsPsychotropic medicationsFollicular phaseMenstrual cycleDHEA ratioExcitatory neurotransmissionNeurotransmitter systemsRe-experiencing symptomsDepressive symptomsPTSD subjectsFluid levelsGroup differencesIllicit drugsWomenNeurotransmissionProgesterone
2005
N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder
Lafleur DL, Pittenger C, Kelmendi B, Gardner T, Wasylink S, Malison RT, Sanacora G, Krystal JH, Coric V. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology 2005, 184: 254-256. PMID: 16374600, DOI: 10.1007/s00213-005-0246-6.Peer-Reviewed Original ResearchConceptsRefractory obsessive-compulsive disorderObsessive-compulsive disorderN-acetylcysteineGlutamatergic neurotransmissionUse of NACYale-Brown Obsessive Compulsive Scale scoresSerotonin reuptake inhibitorsEfficacy of augmentationRecent clinical reportsTreatment of OCDCompulsive Scale scoresNAC augmentationGlutamatergic dysfunctionReuptake inhibitorsLabel usePsychiatric disordersClinical reportsScale scoreModulating agentsDisordersSingle casePatientsFluvoxamineNeurotransmissionOCD symptoms
2003
Clinical Studies Implementing Glutamate Neurotransmission in Mood Disorders
SANACORA G, ROTHMAN DL, MASON G, KRYSTAL JH. Clinical Studies Implementing Glutamate Neurotransmission in Mood Disorders. Annals Of The New York Academy Of Sciences 2003, 1003: 292-308. PMID: 14684453, DOI: 10.1196/annals.1300.018.Peer-Reviewed Original Research
1993
Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients
Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. American Journal Of Psychiatry 1993, 150: 1408-1410. PMID: 8102512, DOI: 10.1176/ajp.150.9.1408.Peer-Reviewed Original ResearchConceptsNeuroleptic-free schizophrenic patientsInterleukin-2Dopaminergic neurotransmissionSchizophrenic patientsElevated CSF levelsAbnormal brain morphologyInterleukin-1 alphaAutoimmune phenomenaCSF levelsHealthy subjectsBrain morphologyPatientsElevated levelsNeurotransmissionCell growthAutoimmunityLevelsSchizophrenia